Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 979 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stability Clear all
Completed Phase 3 Interventional

Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

NCT01659580
View directory record Official record
Conditions
Angina Pectoris
Interventions
T89 high dose, T89 Low dose, Sanqi+Bingpian, Placebo
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
20 Years to 80 Years
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
30
States / cities
Little Rock, Arkansas • Banning, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

NCT01590459
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
VX-509, VX-509 matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
31
States / cities
Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

NCT02037074
View directory record Official record
Conditions
Schizophrenia
Interventions
Drug: EVP-6308, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Medial Branch Radiofrequency Ablation and Lumbar Multifidi

NCT03744260
View directory record Official record
Conditions
Spondylosis, Osteoarthritis
Interventions
Patients undergo ultrasound and lumbar MRI
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

NCT02902679
View directory record Official record
Conditions
Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
Interventions
BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2Phase 3 Interventional

Group Cognitive Behavioral Therapy (CBT I) Vs. Quetiapine for Residual Insomnia Impairing Recovery Among Elderly With Stable Major Affective Disorders

NCT00462618
View directory record Official record
Conditions
Insomnia
Interventions
Quetiapine, Cogntive behavioral therapy
Drug · Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
60 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis

NCT01355796
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Xylitol, Hypertonic saline
Drug
Lead sponsor
Joseph Zabner
Other
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

NCT03091920
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
IW-1973, Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
30 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Effect of Dietary Macronutrient Composition

NCT01371396
View directory record Official record
Conditions
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Low-fat diet, Low-carbohydrate diet
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 21, 2026, 9:53 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

NCT07500298
View directory record Official record
Conditions
Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
Interventions
SAR445877, FOLFOX6, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760993
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

NCT01825200
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Afluria
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
2,640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
14
States / cities
Tucson, Arizona • Coral Gables, Florida • Savannah, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 21, 2026, 9:53 AM EDT
Withdrawn Phase 2 Interventional

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

NCT04119830
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Microsatellite Stable, Mismatch Repair Proficient, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Pembrolizumab, Questionnaire Administration, Rintatolimod
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 21, 2026, 9:53 AM EDT
Terminated Phase 1 Interventional

Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer

NCT01407341
View directory record Official record
Conditions
Adult Spinal Cord Neoplasm, Spinal Bone Metastases, Spinal Cord Compression
Interventions
musculoskeletal complications management/prevention, bone graft, quality-of-life assessment, questionnaire administration
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

NCT00496483
View directory record Official record
Conditions
Renal Failure
Interventions
LCP Tacro (tacrolimus), Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 21, 2026, 9:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Stability of Behavioral and Neural Measures of Attention Networks Across Multiple Sessions

NCT04033731
View directory record Official record
Conditions
Stability of Attentional Networks Over Multiple Sessions of Computerized Task
Interventions
Attention Network Task
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 21, 2026, 9:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Work of Breathing and Oxygen Saturation in Infants Receiving High Flow Nasal Cannula (HFNC)

NCT03529994
View directory record Official record
Conditions
High Flow Nasal Cannula
Interventions
Enrollment
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 6 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Assessment of Stability of Mail-in Capillary Hemoglobin A1c Test Kit

NCT00511030
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleepiness and the Risk of Falling

NCT00383357
View directory record Official record
Conditions
Aging, Balance, Sleep
Interventions
zolpidem
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 20, 2007 · Synced Oct 21, 2026, 9:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Postural Stability in Cervical Spinal Myelopathy

NCT03810781
View directory record Official record
Conditions
Cervical Spondylotic Myelopathy
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

NCT02585934
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Angina Prevalence and Provider Evaluation of Angina Relief

NCT01705054
View directory record Official record
Conditions
Stable Coronary Artery Disease CAD
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 21, 2026, 9:53 AM EDT